Guanfacine | α2A Agonist | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / 肾上腺素能受体 / Guanfacine/胍法辛

Guanfacine/胍法辛 {[allProObj[0].p_purity_real_show]}

货号：A436598

Guanfacine is a selective α2A receptor agonist.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Guanfacine/胍法辛化学结构
CAS号：29110-47-2

Guanfacine/胍法辛 3D分子结构
CAS号：29110-47-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Guanfacine/胍法辛纯度/质量文件产品仅供科研

货号：A436598 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: 更多 >

肾上腺素能受体亚型比较

产品名称	Adrenergic Receptor ↓ ↑	α-adrenergic receptor ↓ ↑	β-adrenergic receptor ↓ ↑	纯度
Ivabradine HCl	✔			98%
Maprotiline HCl	✔			98%
Cisatracurium besylate	✔			96%
Yohimbine HCI		✔		99+%
BMY 7378		++ α2C-adrenoceptor, pKi: 6.54 α1D-adrenoceptor, pKi: 5.1	+ β1-adrenoceptor, pIC50: 5.1	97%
Asenapine maleate		++++ α2B-adrenergic receptor, pKi: 8.9 α2A-adrenergic receptor, pKi: 8.9		97%
Piribedil		++ adrenoceptor α2A, pKi: 7.1 adrenoceptor α2C, pKi: 7.2		98%
Prazosin HCl		✔		95%
Silodosin		✔		98%
Phenoxybenzamine HCl		✔		98%
Naftopidil		+++ α1D-adrenergic receptor, Ki: 20 nM α1A-adrenergic receptor, Ki: 3.7 nM		98%
Naftopidil 2HCl		+ α1-adrenergic receptor, IC50: 0.2 μM		99%
Alfuzosin HCl		✔		98%
Terazosin HCl		✔		99%
Atipamezole		✔		95%
Phentolamine methanesulfonate salt		✔		99%
Doxazosin mesylate		✔		99%
Tolazoline HCl		✔		98%
Zenidolol HCl			++++ β2-adrenergic receptor, Ki: 0.7nM β1-adrenergic receptor, Ki: 611nM	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Guanfacine/胍法辛生物活性

描述	Guanfacine is a selective α2A receptor agonist.

Guanfacine/胍法辛临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02204410	Attention Deficit Hyperactivit... 展开 >>y Disorder Deficient Emotional Self-Regulation 收起 <<	Phase 4	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 收起 <<
NCT00684489	Hypertension	Not Applicable	Completed	-	-
NCT01172288	Tourettes Syndrome ... 展开 >> Tic 收起 <<	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Yale Child Study Center New Haven, Connecticut, United States, 06520 收起 <<

Guanfacine/胍法辛参考文献

[1]Kolar D, Keller A, et al. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2008 Apr;4(2):389-403.

[2]Fox H, Sofuoglu M, et al. Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals. J Psychopharmacol. 2015 Mar;29(3):312-23.

Guanfacine/胍法辛实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

4.06mL

0.81mL

0.41mL

20.32mL

4.06mL

2.03mL

40.64mL

8.13mL

4.06mL

Guanfacine/胍法辛技术信息

CAS号	29110-47-2
分子式	C₉H₉Cl₂N₃O
分子量	246.09
SMILES Code	O=C(NC(N)=N)CC1=C(Cl)C=CC=C1Cl
MDL No.	MFCD00865944

别名
运输	蓝冰
InChI Key	INJOMKTZOLKMBF-UHFFFAOYSA-N
Pubchem ID	3519

存储条件	In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, 2-8°C

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02204410	Attention Deficit Hyperactivit... 展开 >>y Disorder Deficient Emotional Self-Regulation 收起 <<	Phase 4	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 收起 <<
NCT00684489	Hypertension	Not Applicable	Completed	-	-
NCT01172288	Tourettes Syndrome ... 展开 >> Tic 收起 <<	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Yale Child Study Center New Haven, Connecticut, United States, 06520 收起 <<
NCT02204410	-		Completed	-	-
NCT00142948	Heroin Dependence	Phase 2	Completed	-	Russian Federation ... 展开 >> Saint Petersburg Pavlov State Medical University Saint Petersburg, Russian Federation 收起 <<
NCT00223717	Hypertension	Phase 1	Completed	-	United States, Tennessee ... 展开 >> Vanderbilt University Nashville, Tennessee, United States, 37232 收起 <<
NCT01172288	-		Completed	-	-
NCT00109642	-		Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01133847	Attention Deficit Hyperactivit... 展开 >>y Disorder Reading Disabilities 收起 <<	Phase 4	Completed	-	United States, Ohio ... 展开 >> Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45206 United States, Texas University of Texas Health Science Center Houston, Texas, United States, 77030 收起 <<
NCT00919867	Healthy	Phase 1	Completed	-	United States, New Jersey ... 展开 >> Advanced Biomedical Research, Inc. Hackensack, New Jersey, United States 收起 <<
NCT03337646	Attention Deficit Hyperactivit... 展开 >>y Disorder Autism Spectrum Disorder 收起 <<	Phase 4	Recruiting	October 2019	Canada, Ontario ... 展开 >> Center for Pediatric Excellence Recruiting Ottawa, Ontario, Canada, K2G1W2 Contact: Judy van Stralen, MD 6137267355 judy@cfpe.ca Contact: Amanda Smart 6137267355 amanda@cfpe.ca Principal Investigator: Judy van Stralen, MD 收起 <<
NCT00919867	-		Completed	-	-
NCT01133847	-		Completed	-	-
NCT00151996	Attention Deficit Disorder Wit... 展开 >>h Hyperactivity 收起 <<	Phase 2	Completed	-	-
NCT00151996	-		Completed	-	-
NCT02136147	-		Enrolling by invitation	-	Sweden ... 展开 >> Division for Child and Adolescent Psychiatry in Stockholm Stockholm, Stockholm county, Sweden 收起 <<
NCT00152009	Attention Deficit Disorder Wit... 展开 >>h Hyperactivity 收起 <<	Phase 3	Completed	-	-
NCT00150592	-		Completed	-	-
NCT02788851	Attention Deficit Hyperactivit... 展开 >>y Disorder (ADHD) 收起 <<	Not Applicable	Active, not recruiting	December 2018	Canada, Quebec ... 展开 >> Montreal Children's Hospital Montreal, Quebec, Canada, H4A 3J1 收起 <<
NCT00150618	Attention Deficit Disorder Wit... 展开 >>h Hyperactivity 收起 <<	Phase 3	Completed	-	-
NCT00150618	-		Completed	-	-
NCT00150592	Attention Deficit Disorder Wit... 展开 >>h Hyperactivity 收起 <<	Phase 2	Completed	-	-
NCT00901576	Healthy	Phase 1	Completed	-	United States, New Jersey ... 展开 >> Advanced Biomedical Research, Inc. Hackensack, New Jersey, United States, 07601 收起 <<
NCT00901576	-		Completed	-	-
NCT00734578	ADHD	Phase 3	Completed	-	-
NCT00152009	-		Completed	-	-
NCT01470469	-		Completed	-	-
NCT00025779	Attention Deficit Disorder Wit... 展开 >>h Hyperactivity Autistic Disorder Pervasive Development Disorders 收起 <<	Not Applicable	Completed	-	United States, California ... 展开 >> UCLA Neuropsychiatric Institute Los Angeles, California, United States, 90024 United States, Connecticut Yale Child Study Center New Haven, Connecticut, United States, 06520 United States, Indiana Indiana University-Riley Hospital for Children Indianapolis, Indiana, United States, 46202 United States, Maryland Kennedy Krieger Institute Baltimore, Maryland, United States, 21231 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 收起 <<
NCT00613015	Cocaine Related Disorders	Phase 2	Completed	-	United States, South Carolina ... 展开 >> Medical University of South Carolina-GCRC Charleston, South Carolina, United States, 29425 收起 <<
NCT00613015	-		Completed	-	-
NCT01985581	-		Completed	-	-
NCT00734578	-		Completed	-	-
NCT00389779	Hypertension	Phase 3	Completed	-	-
NCT01985581	Attention Deficit Hyperactivit... 展开 >>y Disorder 收起 <<	Phase 4	Completed	-	Canada, Ontario ... 展开 >> JPM van Stralen Medicine Professional Corporation Ottawa, Ontario, Canada, K2G1W2 收起 <<
NCT00004376	Tourette Syndrome	Phase 3	Completed	-	-
NCT00429273	Attention Deficit Disorder Wit... 展开 >>h Hyperactivity 收起 <<	Phase 4	Completed	-	United States, California ... 展开 >> University of California Los Angeles Los Angeles, California, United States, 90095 收起 <<
NCT00773357	Smoking	Phase 2	Active, not recruiting	July 2019	United States, Connecticut ... 展开 >> Yale Center for Clinical Investigation, Yale University New Haven, Connecticut, United States, 06519 收起 <<
NCT00389675	Hypertension	Phase 3	Terminated(Study DAR-312 did n... 展开 >>ot meet its primary co-endpoints.) 收起 <<	-	-
NCT02259517	Attention Deficit Hyperactivit... 展开 >>y Disorder 收起 <<	Not Applicable	Recruiting	July 2020	United States, New York ... 展开 >> New York State Psychiatric Institute Recruiting New York, New York, United States, 10032 Contact: Jonathan Posner, MD 646-774-5735 PosnerJ@nyspi.columbia.edu Principal Investigator: Jonathan Posner, MD 收起 <<
NCT00429273	-		Completed	-	-
NCT00018603	Post-Traumatic Stress Disorder	Phase 1	Completed	-	United States, Connecticut ... 展开 >> VA Connecticut Healthcare System West Haven, Connecticut, United States, 06516 收起 <<
NCT00353379	Schizotypal Personality Disord... 展开 >>er Personality Disorders 收起 <<	Phase 4	Terminated(low enrollment)	-	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT01470469	Generalized Anxiety Disorder (... 展开 >>GAD) Anxiety, Separation Phobia, Social 收起 <<	Phase 2	Completed	-	-
NCT00997984	Attention-Deficit/Hyperactivit... 展开 >>y Disorder 收起 <<	Phase 3	Completed	-	-
NCT00367835	-		Completed	-	-
NCT01244490	-		Completed	-	-
NCT00997984	-		Completed	-	-
NCT01081145	Attention-deficit/Hyperactivit... 展开 >>y Disorder 收起 <<	Phase 3	Completed	-	-
NCT00367835	ADHD	Phase 3	Completed	-	-
NCT00358969	Borderline Personality Disorde... 展开 >>r 收起 <<	Not Applicable	Unknown	-	United States, New York ... 展开 >> Mount Sinai Hospital - Mood & Personality Research Group Recruiting New York, New York, United States, 10029 收起 <<
NCT00585754	Cocaine Dependent ... 展开 >> Alcohol Dependent 收起 <<	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Yale University School of Medicine: Yale Stress Center New Haven, Connecticut, United States, 06519 收起 <<
NCT01244490	Attention Deficit Hyperactivit... 展开 >>y Disorder 收起 <<	Phase 3	Completed	-	-
NCT01177306	Attention Deficit Hyperactivit... 展开 >>y Disorder 收起 <<	Phase 4	Completed	-	United States, North Carolina ... 展开 >> 3C Family Services Cary, North Carolina, United States, 27513 收起 <<
NCT01681264	Chronic Pain	Phase 4	Recruiting	March 2019	United States, Massachusetts ... 展开 >> Center for Translational Pain Research Recruiting Boston, Massachusetts, United States, 02114 Contact: Sarah Roth, B.S 617-724-6102 sroth3@mgh.harvard.edu Principal Investigator: Jianren Mao, M.D., Ph.D. 收起 <<
NCT02048241	Intermittent Explosive Disorde... 展开 >>r Childhood Aggression Oppositional Defiant Disorder Attention Deficit Disorder 收起 <<	Phase 4	Completed	-	United States, New York ... 展开 >> New York State Psychiatric Institute New York, New York, United States, 10032 收起 <<
NCT01081145	-		Completed	-	-
NCT00672984	Healthy Volunteers	Phase 1	Completed	-	United States, Washington ... 展开 >> Charles River Clinical Services Northwest, Inc. Tacoma, Washington, United States 收起 <<
NCT00672984	-		Completed	-	-
NCT00935493	-		Completed	-	-
NCT01081132	Attention-Deficit/Hyperactivit... 展开 >>y Disorder 收起 <<	Phase 3	Completed	-	-
NCT00935493	Cognitive Aging	Not Applicable	Completed	-	United States, Connecticut ... 展开 >> Alzheimer's Disease Research Unit, Yale University School of Medicine New Haven, Connecticut, United States, 06510 收起 <<
NCT02524899	Schizotypal Personality Disord... 展开 >>er SPD 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT03116126	Alzheimer Disease	Phase 3	Not yet recruiting	September 2019	United Kingdom ... 展开 >> Imperial Memory Unit, Charing Cross Hospital Recruiting London, United Kingdom, W6 8RF Contact: Team 020 3311 5228 MEMORY.RESEARCH@IMPERIAL.NHS.UK 收起 <<
NCT01081132	-		Completed	-	-
NCT00955253	Stroke Hemisp... 展开 >>atial Neglect 收起 <<	Phase 2	Completed	-	United Kingdom ... 展开 >> Imperial College Healthcare NHS Trust London, United Kingdom, W6 8RF 收起 <<
NCT00469664	Schizophrenia ... 展开 >> Schizoaffective Disorder Cognitive Impairment 收起 <<	Phase 4	Unknown	December 2008	United States, New York ... 展开 >> Bronx VA Medical Center Bronx, New York, United States, 10468 Mount Sinai Medical Center NY, New York, United States, 10029 Pilgrim Psychiatric Center W. Brentwood, New York, United States, 11717 收起 <<
NCT01238575	Pervasive Development Disorder... 展开 >>s 收起 <<	Phase 4	Completed	-	United States, California ... 展开 >> University of California, Los Angeles Los Angeles, California, United States, 90024 United States, Connecticut Yale University New Haven, Connecticut, United States, 06519 United States, Georgia Emory University Atlanta, Georgia, United States, 30329 United States, Massachusetts Massachusetts General Hospital Lexington, Massachusetts, United States, 02142 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98101 收起 <<
NCT02699125	Obstructive Sleep Apnea	Phase 4	Unknown	August 2016	-
NCT01238575	-		Completed	-	-
NCT01500694	-		Completed	-	-
NCT01547000	Tourette Disorder ... 展开 >> Tourette Syndrome 收起 <<	Phase 4	Completed	-	United States, Connecticut ... 展开 >> Yale Child Study Center New Haven, Connecticut, United States, 06510 United States, Florida University of South Florida Tampa, Florida, United States, 33612 United States, New York Mount Sinai School of Medicine New York, New York, United States, 10029 收起 <<
NCT01146002	Attention-deficit/Hyperactivit... 展开 >>y Disorder 收起 <<	Phase 4	Completed	-	United States, New Jersey ... 展开 >> Neurology Group of Bergen County Ridgewood, New Jersey, United States, 07450 收起 <<
NCT01500694	Attention Deficit Hyperactivit... 展开 >>y Disorder (ADHD) 收起 <<	Phase 3	Completed	-	-
NCT01600885	-		Completed	-	-
NCT01709695	ADHD Attentio... 展开 >>n Deficit Hyperactivity Disorder 收起 <<	Phase 4	Completed	-	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT01600885	NMDA Receptor Function	Not Applicable	Completed	-	United States, Connecticut ... 展开 >> Connecticut Mental Health Center New Haven, Connecticut, United States, 06511 Yale Magnetic Resonance Research Center New Haven, Connecticut, United States, 06520 Veterans Affairs Hospital West Haven, Connecticut, United States, 06516 收起 <<
NCT03333668	ADHD	Not Applicable	Not yet recruiting	December 31, 2020	United Kingdom ... 展开 >> Institute of Psychiatry, Psychology & Neuroscience; King's College London Not yet recruiting London, United Kingdom, SE5 8AF Contact: Olivia S Kowalczyk, BSc 02078480384 oliwia.s.kowalczyk@kcl.ac.uk Principal Investigator: Olivia S Kowalczyk, BSc Sub-Investigator: Katya Rubia, PhD Sub-Investigator: Mitul A Mehta, PhD 收起 <<
NCT01709695	-		Completed	-	-
NCT01547000	-		Completed	-	-
NCT03662763	Attention Deficit Disorder	Phase 3	Completed	-	Netherlands ... 展开 >> Maastricht University Medical Centre Maastricht, Netherlands 收起 <<
NCT01069523	Attention Deficit Disorder Wit... 展开 >>h Hyperactivity 收起 <<	Phase 4	Completed	-	United States, Texas ... 展开 >> Dept. Of Psychiatry, University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229-3900 收起 <<
NCT01156051	-		Terminated(extended beyond com... 展开 >>pletion date; chose to close out rather than renew IRB review) 收起 <<	-	-
NCT02164422	Alcohol Drinking	Phase 2	Recruiting	January 2020	United States, Connecticut ... 展开 >> Yale Center for Clinical Investigations, Yale University Recruiting New Haven, Connecticut, United States, 06519 Contact: Paula Cunningham 203-737-3554 Principal Investigator: Sherry A McKee, PhD 收起 <<
NCT01156051	Attention-Deficit/Hyperactivit... 展开 >>y Disorder Attention Deficit Disorder Insomnia Sleep Disorders 收起 <<	Phase 4	Terminated(extended beyond com... 展开 >>pletion date; chose to close out rather than renew IRB review) 收起 <<	-	United States, New Jersey ... 展开 >> Children's Specialized Hospital Hamilton, New Jersey, United States, 08619 Children's Specialized Hospital Toms River, New Jersey, United States, 08755 收起 <<
NCT02048241	-		Completed	-	-
NCT02882854	Postoperative Nausea and Vomit... 展开 >>ing Pain, Postoperative 收起 <<	Not Applicable	Unknown	July 2017	United States, Tennessee ... 展开 >> Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37212 Principal Investigator: Stephen Harvey, MD 收起 <<
NCT03258476	Stress Disorder	Phase 4	Not yet recruiting	May 2022	United States, Connecticut ... 展开 >> UConn Health Not yet recruiting Farmington, Connecticut, United States, 06030 收起 <<
NCT02192398	Chronic Pain	Not Applicable	Recruiting	December 2019	United States, Massachusetts ... 展开 >> MGH Center for Translational Pain Research Recruiting Boston, Massachusetts, United States, 02114 Contact: MGH Center for Translational Pain Research 617-724-6102 mghpainresearch@partners.org Principal Investigator: Jianren Mao, M.D., Ph.D. 收起 <<
NCT02141113	Adult Attention-Deficit Hypera... 展开 >>ctivity Disorder 收起 <<	Phase 4	Completed	-	United States, Michigan ... 展开 >> Rochester Center for Behavioral Medicine Rochester Hills, Michigan, United States, 48307 收起 <<
NCT03137082	Alcohol Abstinence	Phase 1 Phase 2	Recruiting	December 2019	United States, New York ... 展开 >> The Clinical Research Center Recruiting East Setauket, New York, United States, 11794 Contact: Antoinette Funaro, MS 631-638-0057 antoinette.funaro@stonybrookmedicine.edu Putnam Hall Outpatient Facility Recruiting Stony Brook, New York, United States, 11794 Contact: David Schlager, MD 631-444-2571 david.schlager@stonybrookmedicine.edu 收起 <<
NCT01069523	-		Completed	-	-
NCT01467999	Cannabis Dependence	Phase 1	Completed	-	United States, New York ... 展开 >> STARS New York, New York, United States, 10032 收起 <<
NCT02051309	Smoking Cessation	Phase 2	Active, not recruiting	November 2019	United States, Connecticut ... 展开 >> Yale Center for Clinical Investigations, Yale University New Haven, Connecticut, United States, 06519 收起 <<
NCT01467999	-		Completed	-	-
NCT01904526	Smoking	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Yale Center for Clinical Investigations, Yale University New Haven, Connecticut, United States, 06519 收起 <<
NCT01904526	-		Completed	-	-
NCT03764098	Alcohol Use Disorder	Phase 2	Not yet recruiting	September 29, 2020	United States, Connecticut ... 展开 >> Yale University School of Medicine Not yet recruiting New Haven, Connecticut, United States, 06519 Contact: Meaghan Lavery 203-737-2783 meaghan.lavery@yale.edu Contact: Sabrina Coppola 203-737-2827 sabrina.coppola@yale.edu Principal Investigator: Sherry McKee, PhD 收起 <<

Guanfacine/胍法辛 {[allProObj[0].p_purity_real_show]}

Guanfacine/胍法辛纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Guanfacine/胍法辛质控信息

Guanfacine/胍法辛生物活性

Guanfacine/胍法辛临床研究

Guanfacine/胍法辛参考文献

Guanfacine/胍法辛实验方案

Guanfacine/胍法辛技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Guanfacine/胍法辛 {[allProObj[0].p_purity_real_show]}

Guanfacine/胍法辛 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Guanfacine/胍法辛 质控信息

Guanfacine/胍法辛 生物活性

Guanfacine/胍法辛 临床研究

Guanfacine/胍法辛 参考文献

Guanfacine/胍法辛 实验方案

Guanfacine/胍法辛 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Guanfacine/胍法辛纯度/质量文件产品仅供科研

Guanfacine/胍法辛质控信息

Guanfacine/胍法辛生物活性

Guanfacine/胍法辛临床研究

Guanfacine/胍法辛参考文献

Guanfacine/胍法辛实验方案

Guanfacine/胍法辛技术信息